Stockscreener 앱 받기
13.50
1.32%
-0.18
Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer - GlobeNewswire Inc.
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - GlobeNewswire Inc.
HCM Q2 2023 Earnings: EPS Beat Consensus by 149.86% as Shares Edge HigherAnnual Report - dars.gov.et
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy - BioSpectrum Asia
Trinity Delta Lighthouse: HUTCHMED - Vox Markets
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap UpWhat's Next? - MarketBeat
Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion - finance.biggo.com
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com
GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy - GlobeNewswire
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat
HUTCHMED’s SANOVO Phase III Trial Demonstrates Significant PFS Advantage for ORPATHYS Plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer - Kalkine Media
HUTCHMED (HCM) lung cancer combo tops China Phase III trial - Stock Titan
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China - Barchart.com
HUTCHMED (China) LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response - Stock Titan
HUTCHMED (China) LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordAnalyst Earnings Estimate - careplusvn.com
HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordFinancial Data - dars.gov.et
HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordNet Income Trends - dars.gov.et
HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordSegment Revenue Breakdown - dars.gov.et
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeShould You Buy? - MarketBeat
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success - TradingView
HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case - Stock Titan
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionEarnings Deceleration Risk - careplusvn.com
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionProfit Margin Analysis - dars.gov.et
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionEarnings Season Outlook - dars.gov.et
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionEarnings Cycle Outlook - dars.gov.et
HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionNet Income Trends - dars.gov.et
HUTCHMED (HCM) lung cancer combo extends survival after TAGRISSO - Stock Titan
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusDelta Hedging - vinanet.vn
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusStrangle Setup - careplusvn.com
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusMomentum Breakout Ideas - dars.gov.et
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusVolatility Skew - dars.gov.et
Hutchmed (HCM) Holds Near $12.47 as Biotech Sector Watches Support LevelFactor Rotation - careplusvn.com
HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving AverageHere's Why - marketbeat.com
REGHutchmed China LtdHUTCHMED Reports 2026 Interim Results - TradingView
HCM Q2 2023 Earnings: Strong EPS Beat Driven by Improved ProfitabilityEarnings Manipulation Risk - careplusvn.com
HCM Q2 2023 Earnings: Strong EPS Beat Driven by Improved ProfitabilityCash Flow Report - dars.gov.et
1.02%
자본화:
|
볼륨(24시간):